ZYBERNO
Stock Report
Updated Sep 1, 2026

Tempest Therapeutics, Inc. (TPST)

Healthcare • NASDAQ

$1.09

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
4.0/100
POOR BUSINESS
Tempest Therapeutics, Inc. (TPST) scores 4/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-1,270.1%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-535.6%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Tempest Therapeutics, Inc. (TPST) stock report — Zyberno Score 4/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, TPST generated -$26.38M in Owner Earnings. Reinvestment rate: 0.9%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.09
Market Cap:$16.59M

Valuation Multiples (1)

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$23.38M

Price Action & Momentum (1)

% of 52-Week High:8.9%
B. Profitability Assessment

Return Metrics (5)

ROA:-297.4%
Reinvestment Rate:0.9%
Fundamental Growth Rate (g):-4.7%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$391.13
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:81.3%
Latest Earnings Filed:2026-08-13
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.38x
Quick Ratio:0.38x
Cash Ratio:0.18x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:-2,753,000.00
Cash And Cash Equivalents:779,000.00
Long Term Debt:$6.27M
Net Debt:$6.78M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$40.64M

Bottom Line Performance (3)

-$40.47M
Income Before Tax:$0.00
Ebitda Ttm:-40,392,000.00

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:3,041,000.00
Sga Expense:15,421,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$9.63M
Current Assets:$1.70M
Ppe Net:2,058,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:10,723,000.00
Current Liabilities:4,450,000.00
Long Term Debt:$6.27M
Short Term Debt:$1.29M

Equity & Capital (3)

Equity:-$1.09M
Retained Earnings:-$275.32M
Common Stock:100,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:1,995,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:-117,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$26.38M-$26.38M

Investment Activities (2)

Investing Cash Flow:$0.00
Capital Expenditures Ttm:0.00

Financing Activities (3)

Financing Cash Flow:$1.70M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:6,045,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:250,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-3.97
-$3.97
Earnings Per Share Ttm:-$2.66

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$1.76

Book Value & Capital (2)

Book Value Per Share:-$0.07
Cash Per Share:0.05

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:0.00
Quality Score:5.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$26.38M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.9%
Fundamental Growth Rate (g):-4.7%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-39.7%
C. Company Profile & Context

Corporate Information (6)

Symbol:TPST
Company Name:Tempest Therapeutics, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:15.22M
Shares Outstanding Basic:15.22M
Shares Outstanding Diluted:15.22M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 12:50:48 UTC
Data Timestamp:2026-08-21T06:24:34.035218
Scroll to Top